STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases. Sobi has a strong focus on building a sustainable business and ensuring that everyone eligible within its therapeutic areas has access to approved medicines. The report includes the audited Annual report and the Sustainability report, which is Sobi's statutory sustainability report in accordance with the Swedish Annual Accounts Act and based on GRI Standards 2021, inspired by the European Sustainability Reporting Standards (ESRS). The report includes Sobi's Task Force on Climate-related Financial Disclosures (TCFD) report and its EU Taxonomy disclosures. Sobi is transitioning to fulfil the Corporate Sustainability Reporting Directive (CSRD) and its European Sustainability Reporting Standards (ESRS). The aim has been to implement selected parts of the fundamental standard structure in 2024. The report disposition has, therefore, been modified towards the new requirements, and ESRS inspires the report content. Sobi's 2024 Annual and Sustainability Report is available on sobi.com. The Swedish Annual Report is also available in European Single Electronic Format (ESEF). The Swedish ESEF version prevails in case of any queries or conflicts. Sobi Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. Gerard Tobin Head of Investor Relations This information was brought to you by Cision http://news.cision.com https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-annual-and-sustainability-report-for-2024,c4125559 The following files are available for download: https://mb.cision.com/Main/14266/4125559/3351155.pdf Sobi® publishes Annual and sustainability report for 2024Cision View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-annual-and-sustainability-report-for-2024-302415632.html View Comments
Sobi publishes Annual and sustainability report for 2024
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...